HomeBusinessJubilant Life Sciences partners with Gilead Sciences to develop remdesivir

Jubilant Life Sciences partners with Gilead Sciences to develop remdesivir

Most Read

India-based drugmaker Jubilant Life Sciences on Tuesday said that “It’s subsidiary Jubilant Generics Limited has entered into a non-exclusive agreement with Gilead Sciences to manufacture and sell remdesivir in 217 countries including India.”

In a statement issued, Jubilant said, “Under the licensing agreement, the company has the right to receive technology transfers through the Gilead manufacturing process to scale up production to enable expedited access of the drug to the COVID-19 patients upon the approval by regulatory authorities in their respective countries.”

- Advertisement -

Earlier, Gilead said that “It is in talks with several chemical and drug makers to produce its experimental COVID-19 drug remdesivir for Europe, Asia, and the developing world.”

Speaking on the partnership, Shyam Bhartia and Hari Bhartia, Co-Chairman and Managing Director, Jubilant Life Sciences said, “We are happy to strengthen our partnership with Gilead to license remdevisir. Based on initial data shows promise to be a potential therapy for coronavirus, a pandemic creating unprecedented health and global economic crisis.”

“We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug’s active pharmaceutical ingredient (“API”) in-house, helping it achieve cost-effectiveness and consistent availability,” it added.

Last week, Gilead received the US Food and Drug Administration’s emergency use authorization for using remdesivir as a treatment against COVID-19, after it provided data showing the drug had helped COVID-19 patients.

It has also received Emergency Use Authorization (EUA) from USFDA to treat COVID-19 patients, which allows broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease.

Subscribe To Morning Newsletters

Sign up to receive the latest news stories, exclusive interviews, and more in your inbox.

We don’t spam! Read our privacy policy for more info.

Editor's Pick

Krishna Mali
Krishna Mali
Founder, CEO & Group Editor of TechGraph.

Read More Stories

SKF Showcases Intelligent & Clean Solutions for the Textile Industry at International Textile Machinery Exhibition (ITME) 2022

SKF India, the country's leading technology and solutions provider of bearings and services will showcase innovative products and solutions...

OneRare and Cornitos: Bringing the Magic of Cornitos to the Foodverse

Cornitos is a leader in the Snack category and has always strived to give its fans and patrons the...

Chitkara University Signs MoU with NEC Corporation India to Transform Learning in the Field of AI/ML

Chitkara University announced its collaboration with NEC Corporation India, a wholly owned subsidiary of NEC Corporation, for a comprehensive...

Role of skills-based hiring in promoting inclusive economic growth in India

In recent years, India's employment landscape has experienced a profound shift, with an increasing emphasis on skills-based hiring. This...

Global Cryptocurrency Regulations: Impact on Industry and Investor Behavior in 2024

The world of cryptocurrency has seen remarkable growth and evolution since its inception, transitioning from obscure digital assets to...

Interview: Modernizing Field Sales Operations With Delta Sales App Director Ekta Golchha

Speaking with TechGraph, Ekta Golchha, Founder and Director of Delta Sales App underscores the app's innovative role in optimizing...